Sacred lotus (Nelumbo nucifera) and drug testing
What 2 graded rows on sacred lotus (nelumbo nucifera) agree on for drug testing, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Sacred lotus (Nelumbo nucifera) page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Sacred lotus (Nelumbo nucifera) page, with its PubMed record.
Your question
Sacred lotus (Nelumbo nucifera) and drug testing
2 rows · 20 peopleThey agree: both rows found a worse outcome.
- DGrade D× 2
- Rows
- 2
- Trials
- 2
- People
- 20
What the rows share
From the rowsThe best-graded row, grade D, is a PK study of 14 people (2019) and found a worse outcome.
The rows run from 6 to 14 people, published from 2019 to 2020: 2 single studies.
The rows
2 worse- DGrade DUrinary higenamine above the anti-doping reporting limit · Worse
PK study · n 14 · 2019 · Volunteers
6 x 0.34 g capsules/day · 7 days
Urinary higenamine exceeded the WADA reporting limit (10 ng/mL) during dosing in most sample groups, peaking at 500 ng/mL. The authors judged the risk of a positive test high.
Row on the Sacred lotus (Nelumbo nucifera) page · PubMed 31680485 (opens PubMed)
- DGrade DUrinary higenamine above the anti-doping reporting limit · Worse
PK study · n 6 · 2020 · Volunteers (Taiwan)
0.8 g three times daily (about 680 mcg higenamine per dose) · 3 days
All six participants had urinary higenamine above the WADA reporting cut-off of 10.0 ng/mL. The authors advise athletes to avoid lotus plumule products in and out of competition.
Row on the Sacred lotus (Nelumbo nucifera) page · PubMed 31973198 (opens PubMed)